- Home
- AUST vs NRSN Comparison
AUST vs NRSN Comparison
Compare AUST & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AUST | NRSN |
|---|---|---|
| Founded | 2020 | 2017 |
| Country | Canada | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2M | 26.4M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AUST | NRSN |
|---|---|---|
| Price | $2.20 | $0.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | ★ 2.9M | 307.0K |
| Earning Date | 02-26-2026 | 04-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.05 | $0.68 |
| 52 Week High | $3.92 | $2.60 |
Technical Indicators
Market Signals| Indicator | AUST | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 67.30 | 46.00 |
| Support Level | $1.71 | $0.92 |
| Resistance Level | $3.92 | $1.08 |
| Average True Range (ATR) | 0.34 | 0.10 |
| MACD | 0.06 | -0.00 |
| Stochastic Oscillator | 26.60 | 30.45 |
Price Performance
Historical ComparisonAbout AUST Austin Gold Corp.
Austin Gold Corp is focused on the acquisition, exploration and evaluation of mineral resource properties in the western United States of America (USA). Exploration and development of mineral projects is considered the Company's single business segment. Its projects include Kelly Creek in Humboldt County, Lone Mountain and Miller in Elko County, and Stockade Mountain (Oregon).
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.